Best Penny Stocks Under 25 Cents Right Now → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. These penny stocks all have a super-low share price of $0.25 or less and are sorted by average trading volume in dollars. These companies are considered the most actively-traded stocks priced under $0.25. Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - FiskerNYSE:FSRStock Price: $0.09 (-$0.04)P/E Ratio: -0.04Market Cap: $31.45 millionAverage Trading Volume: 85.29 million sharesConsensus Rating: Reduce (1 Buy Ratings, 4 Hold Ratings, 4 Sell Ratings)Consensus Price Target: $2.76 (2,972.0% Upside)Fisker Inc. develops, manufactures, markets, leases, or sells electric vehicles. It operates through three segments: The White Space, The Value Segment, and The Conservative Premium segments. The company is also involved in asset-light automotive business. In addition, it offers fisker flexible platform agnostic design, a process that develops and designs electric vehicles in specific segment size. The company was incorporated in 2016 and is headquartered in Manhattan Beach, California. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Kintara TherapeuticsNASDAQ:KTRAStock Price: $0.15 (-$0.01)P/E Ratio: -0.02Market Cap: $6.17 millionAverage Trading Volume: 13.71 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AKintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.#3 - Workhorse GroupNASDAQ:WKHSStock Price: $0.16P/E Ratio: -0.27Market Cap: $49.39 millionAverage Trading Volume: 10.77 million sharesConsensus Rating: Hold (1 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $1.50 (855.4% Upside)Workhorse Group Inc., a technology company, engages in design, manufacture, and sale of zero-emission commercial vehicles in the United States. The company offers commercial vehicles under the Workhorse brand. The company was formerly known as AMP Holding Inc. and changed its name to Workhorse Group Inc. in April 2015. Workhorse Group Inc. was founded in 2007 and is headquartered in Sharonville, Ohio.#4 - Sintx TechnologiesNASDAQ:SINTStock Price: $0.04P/E Ratio: -0.01Market Cap: $916,000.00Average Trading Volume: 22.16 million sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ASintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.#5 - Yield10 BioscienceNASDAQ:YTENStock Price: $0.22 (-$0.02)P/E Ratio: -0.11Market Cap: $3.42 millionAverage Trading Volume: 3.95 million sharesConsensus Rating: Hold (1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.50 (1,478.0% Upside)Yield10 Bioscience, Inc. operates as agricultural bioscience company in the United States. The company primarily focus on production of low carbon products through processing Camelina seeds. Its products include Camelina oil for low carbon biofuel feedstock; Omega-3 oils for nutrition; and PHA bioplastics for biodegradable zero waste packaging solutions. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts.#6 - Pineapple EnergyNASDAQ:PEGYStock Price: $0.06 (+$0.01)P/E Ratio: -0.04Market Cap: $4.01 millionAverage Trading Volume: 13.44 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.50 (3,893.6% Upside)Pineapple Energy Inc. engages in the sale, design, and installation of photovoltaic solar energy systems and battery storage systems in the United States. Its brand portfolio includes SUNation, Hawaii Energy Connection, E-Gear, Sungevity, and Horizon Solar Power. The company develops and manufactures energy management software and hardware, such as energy management control devices on solar systems that are paired with batteries. It primarily serves residential homeowners, as well as commercial owners, other municipal customers, energy services companies, and other utilities. Pineapple Energy Inc. was founded in 1969 and is based in Minnetonka, Minnesota.Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024#7 - Chicken Soup for the Soul EntertainmentNASDAQ:CSSEStock Price: $0.24 (-$0.02)P/E Ratio: -0.01Market Cap: $7.79 millionAverage Trading Volume: 3.28 million sharesConsensus Rating: Hold (2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.00 (1,554.3% Upside)Chicken Soup for the Soul Entertainment, Inc. operates as a streaming video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Popcornflix Comedy, Españolflix, and FrightPix. The company distributes and exhibits content through the Crackle Plus and Redbox streaming services including AVOD, FAST, TVOD platforms, such as connected TVs, smartphones, tablets, gaming consoles, and the web through its owned and operated platforms. It also produces and licenses movies, television series, and programs; and produces long and short-form video content. Chicken Soup for the Soul Entertainment, Inc. was founded in 2014 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. operates as a subsidiary of Chicken Soup for the Soul Productions, LLC.#8 - Presto AutomationNASDAQ:PRSTStock Price: $0.17P/E Ratio: -0.14Market Cap: $16.07 millionAverage Trading Volume: 3.81 million sharesConsensus Rating: Moderate Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.54 (1,403.8% Upside)Presto Automation Inc. engages in the provision of artificial intelligence (AI) and automation solutions to the restaurant enterprise technology industry in the United States. The company offers Presto Voice, an AI solution to quick service restaurants that completes complex orders, including large orders with multiple menu modifications and add-ons, with limited on-site restaurant staff intervention; and Presto Touch, a pay-at-table tablet solution to casual dining chains that enables self-serve ordering, payment processing, personalization, and gaming experiences for restaurant guests. Presto Automation, Inc. was founded in 2008 and is headquartered in San Carlos, California.#9 - 2UNASDAQ:TWOUStock Price: $0.24P/E Ratio: -0.06Market Cap: $20.10 millionAverage Trading Volume: 2.61 million sharesConsensus Rating: Hold (1 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.31 (1,694.1% Upside)2U, Inc. operates as an online education platform company in the United States and internationally. The company operates through two segments, Degree Program and Alternative Credential. The Degree Program segment provides the technology and services to nonprofit colleges and universities to enable the online delivery of degree programs. This segment targets students seeking an undergraduate or graduate degree. The Alternative Credential segment offers online open courses, executive education programs, technical, skills-based boot camps, and micro-credential programs through nonprofit colleges and universities, and other organizations. This segment targets students seeking to reskill or upskill for career or personal development through shorter duration and lower-priced offerings. It provides a platform that provides technology and technology-enabled services; and edX.org, a marketplace that allows to access various catalog of online offerings, which include free offerings and graduate degrees. The company was formerly known as 2Tor Inc. and changed its name to 2U, Inc. in October 2012. 2U, Inc. was incorporated in 2008 and is headquartered in Lanham, Maryland.#10 - Nauticus RoboticsNASDAQ:KITTStock Price: $0.19 (-$0.01)P/E Ratio: -0.13Market Cap: $11.80 millionAverage Trading Volume: 2.92 million sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.63 (1,807.9% Upside)Nauticus Robotics, Inc. develops and provides ocean robots, software, and services to the ocean industry. The company offers Aquanaut, an autonomous underwater vehicle (AUV) with sensor suite, which provides capability to observe and inspect subsea assets or other subsea features; and Argonaut, a derivative product of the Aquanaut that is used for non-industrial and government applications. It also provides Olympic Arm, a subsea tool; ToolKITT, a cloud software platform, which consists of interrelated products for ocean sensing, manipulation, autonomous behaviors, survey, search and recovery, and manual intervention; and Hydronaut, an optionally crewed vessel that will support the real-time operations of Aquanaut in commercial applications. The company was founded in 2014 and is based in Webster, Texas.#11 - AtrecaNASDAQ:BCELStock Price: $0.08 (-$0.01)P/E Ratio: -0.03Market Cap: $3.17 millionAverage Trading Volume: 6.50 million sharesConsensus Rating: Hold (0 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.00 (4,900.0% Upside)Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024#12 - AkiliNASDAQ:AKLIStock Price: $0.25P/E Ratio: -0.33Market Cap: $19.43 millionAverage Trading Volume: 1.88 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.00 (1,518.1% Upside)Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.#13 - Galera TherapeuticsNASDAQ:GRTXStock Price: $0.19 (-$0.02)P/E Ratio: -0.13Market Cap: $10.12 millionAverage Trading Volume: 2.35 million sharesConsensus Rating: Reduce (0 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)Consensus Price Target: N/AGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.#14 - Asensus SurgicalNYSEAMERICAN:ASXCStock Price: $0.25 (+$0.01)P/E Ratio: -0.78Market Cap: $67.73 millionAverage Trading Volume: 1.53 million sharesConsensus Rating: Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $0.68 (171.1% Upside)Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.#15 - Tonix PharmaceuticalsNASDAQ:TNXPStock Price: $0.17 (+$0.01)P/E Ratio: -0.02Market Cap: $14.24 millionAverage Trading Volume: 2.13 million sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.50 (3,164.1% Upside)Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its development portfolio focuses on central nervous system disorders. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.#16 - Barnes & Noble EducationNYSE:BNEDStock Price: $0.20 (-$0.01)P/E Ratio: -0.13Market Cap: $10.57 millionAverage Trading Volume: 1.53 million sharesConsensus Rating: Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.63 (1,219.8% Upside)Barnes & Noble Education, Inc. operates bookstores for college and university campuses, and K-12 institutions in the United States. It operates through Retail and Wholesale segments. The company sells and rents new and used print textbooks, digital textbooks, and publisher hosted digital courseware through physical and virtual bookstores, as well as directly to students through Textbooks.com. In addition, it offers First Day and First Day Complete access programs; and general merchandise, including collegiate and athletic apparel, school spirit products, lifestyle products, technology products, supplies, graduation products, and convenience items. Further, the company sources, sells, and distributes new and used textbooks; and sells hardware and a software suite of applications that provides inventory management and point-of-sale solutions to approximately 340 college bookstores. Additionally, it offers direct-to-student services. The company operates physical college and university bookstores; virtual bookstores; True Spirit e-commerce websites; pop-up retail locations; customized cafés and stand-alone convenience stores; and a media channel for brands targeting the college demographic. Barnes & Noble Education, Inc. was founded in 1965 and is headquartered in Basking Ridge, New Jersey.Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024#17 - Sonoma PharmaceuticalsNASDAQ:SNOAStock Price: $0.16P/E Ratio: -0.16Market Cap: $2.50 millionAverage Trading Volume: 1.60 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.25 (1,931.3% Upside)Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.#18 - Matinas BioPharmaNYSEAMERICAN:MTNBStock Price: $0.18P/E Ratio: -1.49Market Cap: $38.91 millionAverage Trading Volume: 1.39 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.00 (1,576.9% Upside)Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.#19 - Calidi BiotherapeuticsNYSEAMERICAN:CLDIStock Price: $0.16 (+$0.00)Market Cap: $5.71 millionAverage Trading Volume: 1.36 million sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.25 (1,922.4% Upside)Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.#20 - NuwellisNASDAQ:NUWEStock Price: $0.17 (-$0.12)P/E Ratio: -0.01Market Cap: $1.14 millionAverage Trading Volume: 1.29 million sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ANuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama. Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.#21 - WeWorkNYSE:WEStock Price: $0.12P/E Ratio: 0.00Market Cap: $6.39 millionAverage Trading Volume: 1.61 million sharesConsensus Rating: Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.00 (6,566.7% Upside)WeWork Inc. provides flexible workspace solutions to individuals and organizations worldwide. The company offers workstation, private office, and customized floor solutions; and various amenities and services, such as private phone booths, internet, high-speed business printers and copiers, mail and package handling, front desk services, off-peak building access, common areas, and daily enhanced cleaning solutions. It also provides various value-add services; business and technical service solutions, including professional employer organization and payroll services, remote workforce solutions, human resources benefits, dedicated bandwidth, and IT equipment co-location solutions. In addition, the company offers WeWork All Access, a monthly subscription-based model that allows members to book workspaces, conference rooms, and private offices; WeWork On Demand, which enables users with pay-as-you-go access to book individual workspace or conference rooms at nearby WeWork locations; and WeWork Workplace, a turnkey workspace management solution for landlords, operators, and enterprises. WeWork Inc. was founded in 2010 and is headquartered in New York, New York.#22 - Advent TechnologiesNASDAQ:ADNStock Price: $0.15 (-$0.01)P/E Ratio: -0.09Market Cap: $9.48 millionAverage Trading Volume: 1.17 million sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AAdvent Technologies Holdings, Inc., an advanced materials and technology development company, operates in the fuel cell and hydrogen technology markets in North America, Europe, and Asia. It develops, manufactures, and assembles fuel cell systems and critical components that determine the performance of hydrogen fuel cells and other energy systems. The company offers high-temperature proton exchange membrane (HT-PEM) fuel cells, including membrane electrode assemblies, bipolar plates, and reformers, as well as provides fuel-cell stack assembly and testing services. It serves stationary power, portable power, automotive, aviation, energy storage, and sensor markets. The company is headquartered in Boston, Massachusetts.#23 - Benson HillNYSE:BHILStock Price: $0.20 (+$0.01)P/E Ratio: -0.32Market Cap: $41.42 millionAverage Trading Volume: 876,028 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ABenson Hill, Inc., together with its subsidiaries, operates as a food technology company that unlocks natural genetic diversity of plants. It operates in two segments, Ingredients and Fresh. The company offers CropOS, a technology platform, which uses artificial intelligence, data, and various advanced breeding techniques that combine data, plant, and food sciences to deliver crops optimized for food, ingredient, and feed products. The company's technology is applied in soybeans and yellow peas. It focuses on growing, packing, and selling fresh produce products to retail and food service customers. The company was formerly known as Benson Hill Biosystems, Inc. Benson Hill, Inc. was incorporated in 2012 and is headquartered in Saint Louis, Missouri.#24 - Gamida CellNASDAQ:GMDAStock Price: $0.02P/E Ratio: -0.03Market Cap: $2.77 millionAverage Trading Volume: 9.20 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.75 (26,288.9% Upside)Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.#25 - iSunNASDAQ:ISUNStock Price: $0.17P/E Ratio: -0.22Market Cap: $7.96 millionAverage Trading Volume: 969,804 sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $38.33 (22,717.5% Upside)iSun, Inc., a solar energy company, provides design, development, engineering, procurement, installation, storage, and electric vehicle infrastructure services for residential, commercial, industrial, and utility customers in the United States. It also provides electrical contracting services; and data and communication services. The company was formerly known as The Peck Company Holdings, Inc. and changed its name to iSun, Inc. in January 2021. iSun, Inc. was founded in 1972 and is headquartered in Williston, Vermont. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Alphabet Changes the Narrative with Its First-Ever Dividend Microsoft Fires a Trend Following Signal: Targets Move Higher A Mega Market Reset for Meta Platforms Stock The Bottom is in For Tesla: Read This Before Buying the Bounce GE Aerospace is Ready for Liftoff After Strong Earnings Beyond the Halving: The Future of Bitcoin Mining Stocks Pagaya Technologies: An AI Fintech That Insiders Are Buying Charles Schwab Fortifies its Uptrend on EPS Beat Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.